Terms: = Gastric cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Staging
12 results:
1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
2. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
Nakayama I; Ohashi M; Nunobe S
Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.
Xu C; Xie XL; Kang N; Jiang HQ
BMC Gastroenterol; 2023 Sep; 23(1):298. PubMed ID: 37667169
[TBL] [Abstract] [Full Text] [Related]
4. [Skip metastasis at the esophageal resection margin in radical gastrectomy: clinical characteristics of 30 cases].
Liu S; Xia QY; Fu Y; Lu XF; Wang M; Guan WX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):675-679. PubMed ID: 37583025
[No Abstract] [Full Text] [Related]
5. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic significances of pd-l1- and CTLA-4-positive T cells and positive correlations of immunosuppressive marker expression between cancer tissue and peripheral blood in patients with gastric cancer.
Lee KH; Kim SJ; Woo JS; Lee SY; Jhun J; Moon J; Jung YJ; Cho ML; Song KY
Front Immunol; 2023; 14():1138743. PubMed ID: 37153541
[TBL] [Abstract] [Full Text] [Related]
7. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
8. A cohort study using IL-6/Stat3 activity and PD-1/pd-l1 expression to predict five-year survival for patients after gastric cancer resection.
Li XN; Peng YH; Yue W; Tao L; Zhang WJ
PLoS One; 2022; 17(12):e0277908. PubMed ID: 36454780
[TBL] [Abstract] [Full Text] [Related]
9. gastric cancer: Emerging Trends in Prevention, Diagnosis, and Treatment.
Norwood DA; Montalvan-Sanchez E; Dominguez RL; Morgan DR
Gastroenterol Clin North Am; 2022 Sep; 51(3):501-518. PubMed ID: 36153107
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Value of pd-l1 Immunohistochemical Marker in gastric Carcinoma and Its Correlation with HER2 Status.
Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706
[TBL] [Abstract] [Full Text] [Related]
11. An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer.
Xing X; Jia S; Leng Y; Wang Q; Li Z; Dong B; Guo T; Cheng X; Du H; Hu Y; Feng Q; Lian S; Luan F; Ma X; Li Z; Ni M; Li Z; Ji J
Oncoimmunology; 2020 Aug; 9(1):1792038. PubMed ID: 32939321
[TBL] [Abstract] [Full Text] [Related]
12. A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III gastric cancer.
Wen T; Wang Z; Li Y; Li Z; Che X; Fan Y; Wang S; Qu J; Yang X; Hou K; Zhou W; Xu L; Li C; Wang J; Liu J; Chen L; Zhang J; Qu X; Liu Y
Cancer Immunol Res; 2017 Jul; 5(7):524-534. PubMed ID: 28619967
[TBL] [Abstract] [Full Text] [Related]
